The Medical Letter on Drugs and Therapeutics
Aptensio XR - Another Long-Acting Methylphenidate for ADHD
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.

The FDA has approved Aptensio XR (Rhodes), an extended-release formulation of methylphenidate hydrochloride, for treatment of attention-deficit/hyperactivity disorder (ADHD). The Aptensio XR capsules contain multilayer beads designed to provide both a rapid onset and a long duration of action. This formulation of methylphenidate has been available in Canada as Biphentin since 2006.

METHYLPHENIDATE — Methylphenidate is effective in reducing the symptoms of ADHD in both children and adults.1,2 The effects of immediate-release methylphenidate products on behavior begin within 30 minutes and last for 3-5 hours; repeat dosing at mid-day is usually required. Long-acting methylphenidate products are dosed once daily. Some generic formulations of Concerta, which has a duration of action of 10-12 hours, have been found to release the drug at a slower ... more      

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this article:
Title: Aptensio XR - Another Long-Acting Methylphenidate for ADHD
Article code: 1473a
 Electronic, downloadable article - $45
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
Recommend to your librarian